Should I buy or sell Arcellx stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACLX shares. View ACLX analyst ratings or view top-rated stocks .

What is Arcellx's stock price target for 2024?

12 equities research analysts have issued 1 year price targets for Arcellx's stock. Their ACLX share price targets range from $50.00 to $87.00. On average, they expect the company's stock price to reach $74.17 in the next year. This suggests a possible upside of 36.1% from the stock's current price. View analysts price targets for ACLX or view top-rated stocks among Wall Street analysts .

How have ACLX shares performed in 2024?

Arcellx's stock was trading at $55.50 at the beginning of the year. Since then, ACLX shares have decreased by 1.8% and is now trading at $54.50. View the best growth stocks for 2024 here .

When is Arcellx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ACLX earnings forecast .

How were Arcellx's earnings last quarter?

Arcellx, Inc. (NASDAQ:ACLX) announced its quarterly earnings results on Wednesday, February, 28th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.95. The firm earned $63.15 million during the quarter, compared to analyst estimates of $20.07 million. Arcellx had a negative net margin of 64.08% and a negative trailing twelve-month return on equity of 20.96%. During the same quarter last year, the business earned ($0.76) earnings per share.

What ETFs hold Arcellx's stock?

ETFs with the largest weight of Arcellx (NASDAQ:ACLX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

When did Arcellx IPO?

Arcellx (ACLX) raised $132 million in an initial public offering on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share.

Who are Arcellx's major shareholders?

Arcellx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Congress Asset Management Co. MA (0.04%), Allspring Global Investments Holdings LLC (0.02%) and High Net Worth Advisory Group LLC (0.02%). Insiders that own company stock include Christopher Heery , Enterprise Associates 15 New, Jill Carroll , Michelle Gilson , Olivia C Ware, Rami Elghandour , Scott D Sandell and Sr One Capital Management, Llc. View institutional ownership trends .

How do I buy shares of Arcellx?

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:ACLX

Arcellx (ACLX) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free ACLX Stock Alerts

$54.50

+0.95 (+1.77%)

(As of 04/18/2024 ET)

Compare

Today's Range: $52.59
▼
$54.89
50-Day Range: $53.55
▼
$73.49
52-Week Range: $30.74
▼
$75.10

Volume: 600,782 shs
Average Volume: 450,100 shs
Market Capitalization: $2.90 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $74.17

Get Arcellx alerts:

Arcellx MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 36.1% Upside
$74.17 Price Target
Short Interest: Bearish
9.85% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.42
Based on 4 Articles This Week
Insider Trading: Selling Shares
$42.44 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.69) to ($1.65) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.71 out of 5 stars

Medical Sector

456th out of 918 stocks

Biological Products, Except Diagnostic Industry

65th out of 147 stocks

4.5

Analyst's Opinion

Consensus Rating
Arcellx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Arcellx has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
9.85% of the float of Arcellx has been sold short.
Short Interest Ratio / Days to Cover
Arcellx has a short interest ratio ("days to cover") of 8.6.
Change versus previous month
Short interest in Arcellx has recently increased by 4.43%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Arcellx does not currently pay a dividend.
Dividend Growth
Arcellx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACLX.

1.9

News and Social Media Coverage

News Sentiment
Arcellx has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Arcellx this week, compared to 3 articles on an average week.
Search Interest
Only 4 people have searched for ACLX on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Arcellx to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arcellx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,439,893.00 in company stock.
Percentage Held by Insiders
Only 5.86% of the stock of Arcellx is held by insiders.
Percentage Held by Institutions
96.03% of the stock of Arcellx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Arcellx are expected to grow in the coming year, from ($1.69) to ($1.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arcellx is -37.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arcellx is -37.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arcellx has a P/B Ratio of 5.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Arcellx Stock (NASDAQ:ACLX)

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

ACLX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACLX Stock News Headlines

April 4, 2024 | insidertrades.com

Arcellx, Inc. (NASDAQ:ACLX) Insider Rami Elghandour Sells 23,086 Shares

March 27, 2024 | insidertrades.com

Arcellx, Inc. (NASDAQ:ACLX) Insider Christopher Heery Sells 5,450 Shares

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 27, 2024 | insidertrades.com

Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $2,902,995.70 in Stock

March 26, 2024 | insidertrades.com

Arcellx, Inc. (NASDAQ:ACLX) Director Sells $35,575,754.65 in Stock

March 19, 2024 | insidertrades.com

Arcellx, Inc. (NASDAQ:ACLX) CFO Michelle Gilson Sells 6,825 Shares

April 13, 2024 | americanbankingnews.com

Arcellx (NASDAQ:ACLX) Stock Rating Reaffirmed by Needham & Company LLC

April 12, 2024 | markets.businessinsider.com

Buy Rating Backed by Potential Regulatory Tailwinds for Arcellx’s CAR-T Therapy

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 11, 2024 | msn.com

3 Best Stocks to Buy Now, 4/11/2024, According to Top Analysts

April 4, 2024 | businesswire.com

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 4, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX) and Adaptive Biotechnologies (ADPT)

March 27, 2024 | finance.yahoo.com

Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares

March 20, 2024 | investing.com

Arcellx director Ware sells over $630k in company stock

March 20, 2024 | businesswire.com

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

March 18, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Arcellx Inc (ACLX) and AdaptHealth (AHCO)

March 16, 2024 | finance.yahoo.com

ACLX Apr 2024 70.000 call

March 7, 2024 | realmoney.thestreet.com

Arcellx initiated with bullish view at Morgan Stanley, here's why

March 2, 2024 | finance.yahoo.com

Earnings Update: Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Are Boosting Their Estimates

February 29, 2024 | markets.businessinsider.com

Anticipating Arcellx Inc. Catalysts: Strong CAR-T Trial Data Underpin Buy Rating

February 29, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Arcellx Inc’s Anito-cel Amid Superior Safety Profile and Strong Market Entry Prospects

February 29, 2024 | prnewswire.com

Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference

February 29, 2024 | finanznachrichten.de

Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights

February 29, 2024 | msn.com

Arcellx Analysts Boost Their Forecasts After Q4 Results

February 29, 2024 | markets.businessinsider.com

William Blair Reaffirms Their Buy Rating on Arcellx Inc (ACLX)

February 28, 2024 | finance.yahoo.com

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights

February 24, 2024 | msn.com

Arcellx (ACLX) Price Target Increased by 6.19% to 68.51

See More Headlines

Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ACLX
CUSIP: N/A
CIK: 1786205
Web: arcellx.com
Phone: 240-327-0603
Fax: N/A
Employees: 130
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $74.17
High Stock Price Target: $87.00
Low Stock Price Target: $50.00
Potential Upside/Downside: +36.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-70,690,000.00
Net Margins: -64.08%
Pretax Margin: -63.48%
Return on Equity: -20.96%
Return on Assets: -10.53%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.06
Quick Ratio: 6.06

Sales & Book Value

Annual Sales: $110.32 million
Price / Sales: 26.33
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.97 per share
Price / Book: 5.47

Miscellaneous

Outstanding Shares: 53,290,000
Free Float: 50,167,000
Market Cap: $2.90 billion
Optionable: Optionable
Beta: 0.02

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Rami Elghandour (Age 45)
Chairman of the Board, CEO & President
Comp: $1.02M
Ms. Michelle Lim Gilson (Age 31)
Chief Financial Officer
Comp: $832.8k
Dr. Christopher R. Heery M.D. (Age 44)
Chief Medical Officer
Comp: $688.55k
Mr. Narinderjeet Singh M.S. (Age 52)
Chief Technical Officer
Mr. David Tice Ph.D. (Age 53)
Chief Scientific Officer
Ms. Myesha Lacy
Chief Investor & Communications Officer
Ms. Maryam Abdul-Kareem J.D.
M.S., General Counsel
Ms. Kate Aiken
Chief People Officer
Mr. Neeraj P. Teotia (Age 49)
Chief Commercial Officer
Comp: $461.95k
Ms. Aileen Fernandes
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcellx stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACLX shares.
View ACLX analyst ratings or view top-rated stocks.
What is Arcellx's stock price target for 2024?: 12 equities research analysts have issued 1 year price targets for Arcellx's stock. Their ACLX share price targets range from $50.00 to $87.00. On average, they expect the company's stock price to reach $74.17 in the next year. This suggests a possible upside of 36.1% from the stock's current price.
View analysts price targets for ACLX or view top-rated stocks among Wall Street analysts.
How have ACLX shares performed in 2024?: Arcellx's stock was trading at $55.50 at the beginning of the year. Since then, ACLX shares have decreased by 1.8% and is now trading at $54.50.
View the best growth stocks for 2024 here.
When is Arcellx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ACLX earnings forecast.
How were Arcellx's earnings last quarter?: Arcellx, Inc. (NASDAQ:ACLX) announced its quarterly earnings results on Wednesday, February, 28th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.95. The firm earned $63.15 million during the quarter, compared to analyst estimates of $20.07 million. Arcellx had a negative net margin of 64.08% and a negative trailing twelve-month return on equity of 20.96%. During the same quarter last year, the business earned ($0.76) earnings per share.

What ETFs hold Arcellx's stock?: ETFs with the largest weight of Arcellx (NASDAQ:ACLX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC).
When did Arcellx IPO?: Arcellx (ACLX) raised $132 million in an initial public offering on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share.
Who are Arcellx's major shareholders?: Arcellx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Congress Asset Management Co. MA (0.04%), Allspring Global Investments Holdings LLC (0.02%) and High Net Worth Advisory Group LLC (0.02%). Insiders that own company stock include Christopher Heery, Enterprise Associates 15 New, Jill Carroll, Michelle Gilson, Olivia C Ware, Rami Elghandour, Scott D Sandell and Sr One Capital Management, Llc.
View institutional ownership trends.
How do I buy shares of Arcellx?: Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACLX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arcellx (ACLX) Stock Price, News & Analysis

Arcellx MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Arcellx Stock (NASDAQ:ACLX)

ACLX Stock Price History

ACLX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACLX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™